Mavens partnered with a leading biotech company to help identify patients with a rare genetic disease.
Misdiagnoses waste valuable time and can profoundly affect the patient’s quality of life.
The company launched their first product into the market ahead of their competition, and sought to maximize this competitive advantage through technology.
Due to the heterogeneous nature of the disease’s symptoms, patients are frequently misdiagnosed. And since this condition is progressive, these misdiagnoses waste valuable time and can profoundly affect the patient’s quality of life.
Our client needed a new way to ensure commercial field teams were providing targeted education to support patient identification and reduce time to diagnosis and ultimately treatment.
Mavens created a cloud-based solution that combines multiple datasets and identifies key patterns.
Datasets are combined to build up comprehensive patient profiles, and to identify the healthcare providers serving these potential patients.
Mavens deployed our Patient Discovery Cloud, a data platform capable of collecting, de-identifying, and analyzing datasets to detect patterns that correlate with the diagnosis of this disease. These datasets are combined to build up comprehensive patient profiles, and to identify the healthcare providers serving these potential patients.
In addition to combining labs, claims, and consumer datasets in a HIPAA-compliant and anonymized database, Patient Discovery Cloud also engages directly with marketing data. The solution tracks individuals searching for information related to the symptoms of this disease or interacting with relevant brand websites.
To help visualize and classify the data, all datasets are scored to prioritize their importance and improve the accuracy of results. For example, a patient receiving a lab test for polyneuropathy and filing a claim for prescription arrhythmia treatment would be highly scored as these symptoms strongly correlate to symptoms of the disease. Our Patient Discovery Cloud solution gives our clients unprecedented control over their market data and its origins.
“The single greatest technology investment we’ve ever made. It’s our secret weapon.”
16 potential patients identified within three months of implementation.
After rollout to a group of pilot users, the immediate feedback was universally positive. Within three months of the technology’s official launch, the program had identified 16 potential patients and users remarked that the platform fundamentally changed the way they worked.